Octozi
Octozi is an AI platform designed for the life sciences industry, specifically biopharma sponsors, to automate critical clinical development processes such as data cleaning and review. By leveraging Generative AI and advanced machine learning analytics, Octozi aims to significantly increase speed to market by accelerating time to market. The platform enhances patient safety through AI-driven early safety signal detection and enables study teams to implement faster corrective actions. It also improves data management by facilitating real-time discrepancy detection, going beyond basic edit checks and traditional RBQM solutions. Octozi's Clinical Science capabilities allow for the visualization and monitoring of clinical data for safety and efficacy. The company's platform is built with security as a core pillar, ensuring compliance and data privacy, and is certified by independent authorities. It is powered by custom-developed large language models (LLMs) tuned specifically for clinical development, differentiating it as the only LLM-powered platform designed for this purpose. Octozi aims to improve quality, reduce time-consuming activities, and lower costs associated with manual processes. Octozi has secured a strategic investment from Debiopharm, highlighting its potential in advancing AI for clinical development. The platform is scalable and extensible, catering to the needs of biotech startups, large pharma, and CROs across various trial phases and therapeutic areas. They emphasize that user data is never used to train models, ensuring data privacy and security.
Octozi
Octozi is an AI platform designed for the life sciences industry, specifically biopharma sponsors, to automate critical clinical development processes such as data cleaning and review. By leveraging Generative AI and advanced machine learning analytics, Octozi aims to significantly increase speed to market by accelerating time to market. The platform enhances patient safety through AI-driven early safety signal detection and enables study teams to implement faster corrective actions. It also improves data management by facilitating real-time discrepancy detection, going beyond basic edit checks and traditional RBQM solutions. Octozi's Clinical Science capabilities allow for the visualization and monitoring of clinical data for safety and efficacy. The company's platform is built with security as a core pillar, ensuring compliance and data privacy, and is certified by independent authorities. It is powered by custom-developed large language models (LLMs) tuned specifically for clinical development, differentiating it as the only LLM-powered platform designed for this purpose. Octozi aims to improve quality, reduce time-consuming activities, and lower costs associated with manual processes. Octozi has secured a strategic investment from Debiopharm, highlighting its potential in advancing AI for clinical development. The platform is scalable and extensible, catering to the needs of biotech startups, large pharma, and CROs across various trial phases and therapeutic areas. They emphasize that user data is never used to train models, ensuring data privacy and security.
TL;DR
What they do: LLM-powered AI agents that automate clinical trial data workflows (discrepancy detection, data cleaning/review, query workflows).
Stage & funding: Pre-Seed; strategic investment from Debiopharm; total funding listed as 150000 USD.
Founded / HQ: Founded 2023; listed address at Future Labs, 370 Jay Street, 7th Floor, New York, NY.
Tech focus: Generative AI / custom LLMs tuned for clinical development; emphasis on security and privacy (user data not used to train models).
Approximately 6 employees (snapshot).
